About Us

Opening a new front in the fight against infectious diseases

Our mission

All around the world, millions of people suffer from pernicious fungal diseases.

At SCYNEXIS, we are bringing a ground-breaking class of drugs to the battle by developing innovative products that have the strength, safety and versatility to defeat even the most insidious fungal diseases.

We are committed to positively impacting the lives of patients suffering from fungal infections — from the most common to the difficult-to-treat and deadliest.

Our work is focused in fungal infections where antimicrobial resistance is a significant concern

  • Life-threatening Infections

    Serious, invasive and often deadly fungal infections treated in the hospital setting are increasingly drug resistant. Our first-in-class antifungal platform can give patients and healthcare professionals innovative new weapons to deploy against these dangerous diseases.

    Learn More

  • Community Infections

    When it comes to fungal infection diseases, women’s health was very much underserved.

    Forgotten. We changed that, by developing ibrexafungerp (BREXAFFEMME®), now partnered with GSK.

Success backed by
strong leadership

Our leaders have deep experience in infectious disease, impressive business acumen and an unwavering commitment to excellence.

Learn More

Make a difference.
Join our team.

We have an unrelenting commitment to making a difference in the lives of patients.

Learn More